v3.26.1
Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2020
USD ($)
Program
Oct. 31, 2018
Program
Jun. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Contract with customer liability, revenue recognized       $ 53,800,000            
2018 Gilead Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Non-refundable upfront payment received           $ 50,000,000   $ 50,000,000    
Number of licensed product | Program   5                
Amended Gilead Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Non-refundable upfront payment received           125,000,000        
Number of licensed product | Program 15                  
Temporary equity, par value $ 125,000,000                  
Research term 7 years                  
Research extension fee                 $ 24,000,000 $ 24,000,000
Amended Gilead Agreement [Member] | Maximum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Milestone payments receivable $ 300,000,000                  
Gilead Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Transaction price allocated to performance obligation     $ 199,000,000     199,000,000        
Collaboration Revenue [Member] | Gilead Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Contract with customer liability, revenue recognized     $ 0   $ 3,200,000 $ 0 $ 8,600,000